Guide
Female biology and type 1 diabetes, across the life stages
A teenager whose first periods land alongside a CGM that the family is still learning to read. A woman in her thirties planning a baby with folic acid on the worktop and a pre-conception HbA1c target in her head. A new mother on a postnatal ward where the insulin dose has just halved overnight. A woman in her fifties whose periods have stopped behaving like a calendar. Female biology adds a recurring pattern on top of the adult system, and the work of this guide is to name the shift before it surprises.
Ask Grace
Want the life-stage-specific answer to the question you came with? Ask Grace for an answer that holds the cycle, contraception, pregnancy and menopause evidence; the NICE NG3 pre-pregnancy targets, CONCEPTT in pregnancy, AiDAPT and CRISTAL on AHCL in pregnancy, and the EMAS practical statement on menopause.
What this guide does, and what it does not
Female biology adds a recurring pattern on top of the adult diabetes system. The cycle, the contraception conversation, the planning of a pregnancy, the pregnancy itself and the first months after, and the menopause and the years around it all move insulin sensitivity in named directions and on different time scales. The foundations of the adult guide still apply to every part of this guide; this is the recurring pattern read alongside the foundations the reader already holds.
What this guide does is name the shifts at each life stage and the conversation each shift earns with the diabetes team. What this guide does not do is hand you a number to take this evening. Every figure on these pages is a population-average reference at your total daily dose, not a personal dose; the dose and settings conversations are with the diabetes team, with the antenatal-diabetes team for the planning and pregnancy parts, and with the menopause team alongside the diabetes team for the years around the end of the cycles.
How the life stages split the work
The split in this guide is the life-stage one, not the calendar one. The reader picks the part that fits the work they are currently doing; in some life stages a reader will sit comfortably in one part, in others a reader will sit at the join of two. The work moves with the life, not with the birthday.
The five parts of the female guide
Part 1, periods as a young person. The first cycles arrive while the diabetes work is still being shared between two pairs of hands. The pattern in the week before the period shows up in the CGM data; the household and the young person read it together at the start.
Part 2, periods in adult life. The adult cycle is the recurring pattern the body already knows. Contraception choices may shift the line; PCOS is more common in T1D than in the general population. A settings review is a care-team conversation, not a self-prescription.
Part 3, planning a baby. Planning a pregnancy with T1D is a shared piece of work that starts well before the test stick changes. NICE NG3 anchors three pre-pregnancy targets; the household and the diabetes team hold the conversation together.
Part 4, pregnancy and after the birth. The densest stretch of diabetes work most women with T1D do. The joint antenatal-diabetes team holds the operational anchor; AHCL with a licensed pregnancy indication runs pregnancy-specific target bands; the postpartum insulin drop is sharp.
Part 5, menopause and the years around it. Cycle variability widens before cycles end. The T1D-specific evidence base is thinner than the work deserves; the part names the gap explicitly and routes the conversation to the menopause team alongside the diabetes team.
The five parts read in order for the reader who wants the whole arc; each part also stands on its own for the reader at a single life stage.
The recurring pattern, named once for the whole hub
The recurring pattern across the life stages is the sensitivity arrow. The cycle nudges it gently each month; contraception can nudge it modestly at the start of a new choice and at three months; the pregnancy timeline reshapes it across three trimesters and then drops it sharply immediately after the birth; the menopause arrives with widening variability before the cycles end and may shift again post-menopause. Each arrow is real, the variation is wide, and the recognition of the arrow is the first lever before any settings change.
Three principles carry across every life stage. The reader’s own CGM data, read across three or four cycles, is the strongest single signal; population averages are the orientation, not the prescription. The settings change after any recognised shift is a care-team conversation; the reader brings the trace and names the pattern, the team holds the change. The household, the antenatal-diabetes team, the menopause team, and the diabetes team are part of the same conversation; the reader is the operational anchor with the teams alongside.
Female biology adds a recurring pattern on top of the adult system. The work is to recognise the shift before it surprises, and to bring the noticing to the care team rather than rewriting the doses alone.
The five parts that follow walk through each life stage in turn, with the foundations the reader already holds carried alongside the recurring pattern this guide adds.
Hub
Female biology and type 1 diabetes, across the life stages
Read more on GNL
References
National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline NG3. 2015, updated 2020. (Pre-pregnancy targets, pregnancy management, postpartum.)
Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. The Lancet. 2017;390(10110):2347-2359.
Lee TTM, Collett C, Bergford S, et al. Automated insulin delivery in women with pregnancy complicated by type 1 diabetes (AiDAPT). New England Journal of Medicine. 2023;389(17):1566-1578.
Benhalima K, Beunen K, Van Wilder N, et al. Advanced hybrid closed-loop in pregnant women with type 1 diabetes (CRISTAL): a randomised controlled trial. The Lancet Diabetes and Endocrinology. 2024;12(6):390-403.
Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6-10.
Courtney HE, Owens DR. Menopause and type 1 diabetes: an unmet need. Endocrine Connections. 2025. (T1D-specific synthesis; names the evidence gap explicitly.)
American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes 2026. Diabetes Care. 2026;49(Suppl 1). (Chapter 15, management of diabetes in pregnancy and women’s health.)